Non-Hodgkin Lymphoma | Specialty

The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.

Durable Responses With GLPG5101 Suggest Feasibility of Decentralized CAR T Manufacturing in R/R NHL

July 9th 2024

GLPG5101 produced high CRs in patients with relapsed/refractory non-Hodgkin lymphoma, indicating the feasibility of decentralized CAR T manufacturing.

Tazemetostat NDA Receives Priority Review in China for R/R Follicular Lymphoma

July 8th 2024

China’s NMPA has granted priority review to an NDA for tazemetostat for the treatment of patients with relapsed/refractory follicular lymphoma.

China’s NMPA Approves Selinexor for R/R DLBCL

July 8th 2024

Selinexor has received approval as monotherapy for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma in China.

STAT3 Degrader KT-333 is Well Tolerated Across R/R Hematologic Malignancies and Solid Tumors

July 6th 2024

KT-333 was well tolerated in relapsed/refractory hematologic and solid tumor cancers, including cutaneous T-cell lymphoma and peripheral T-cell lymphoma.

OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Dr Cherng on Considerations for the Use of Bispecific Antibodies in DLBCL

July 2nd 2024

Hua-Jay “Jeff” Cherng, MD, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with DLBCL.

Epcoritamab Receives Positive CHMP Opinion for Relapsed/Refractory Follicular Lymphoma

June 28th 2024

The EMA’s CHMP has recommended a conditional marketing authorization for epcoritamab for patients with relapsed/refractory follicular lymphoma.

CHMP Recommends Odronextamab for Relapsed/Refractory FL and DLBCL

June 28th 2024

The EMA's CHMP has recommended the conditional marketing authorization of odronextamab for relapsed/refractory FL and DLBCL.

huCART19-IL18 Is Tolerable, Induces Responses in CAR T-Cell–Pretreated R/R Lymphoma

June 27th 2024

Armored huCART19-IL18 treatment was tolerable in patients with relapsed/refractory lymphomas who progressed after CD19-directed CAR T-cell therapy.

Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL

June 27th 2024

Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL.

FDA Modifies REMS for Autologous CAR T-Cell Therapies in Hematologic Malignancies

June 27th 2024

The FDA has modified the risk evaluation and mitigation strategies for CAR T-cell therapies approved for hematologic malignancies.

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

June 27th 2024

Liso-cel continued to show improved disease control and EFS and PFS vs SOC in the second-line treatment of patients with large B-cell lymphoma.

Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL

June 27th 2024

Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.

FDA Grants Accelerated Approval to Epcoritamab for Relapsed/Refractory Follicular Lymphoma

June 26th 2024

The FDA has granted accelerated approval to epcoritamab-bysp (Epkinly) for the treatment of adult patients with relapsed or refractory follicular lymphoma following 2 or more lines of systemic therapy.

Valemetostat Tosilate Approved in Japan for R/R PTCL

June 24th 2024

Valemetostat tosilate has been approved by the Japan Ministry of Health, Labor and Welfare for the treatment of patients with relapsed/refractory PTCL.

China’s NMPA Grants Priority Review to Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

June 20th 2024

Tafasitamab plus lenalidomide has been granted priority review in China for transplant-ineligible, relapsed/refractory diffuse large B-cell lymphoma.

Battiwalla Talks Bispecific Antibodies, BTK Inhibitors, and Emerging Therapies in Hematologic Malignancies

June 19th 2024

Minoo Battiwalla, MD, discusses the role of bispecific antibodies as an alternative to CAR T-cell therapies in NHL, treatment strategies for aggressive follicular lymphomas, and more.

Golidocitinib Green Lit by China’s NMPA for Relapsed/Refractory PTCL

June 19th 2024

Golidocitinib has received approval from China’s NMPA for relapsed/refractory peripheral T-cell lymphoma.

Dr Svoboda on the Investigation of huCART19-IL18 in Relapsed/Refractory Lymphoma

June 18th 2024

Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.

Glofitamab Plus Gemcitabine/Oxaliplatin Shows Survival Benefit in Transplant-Ineligible R/R DLBCL

June 15th 2024

Adding fixed-duration glofitamab-gxbm (Columvi) to gemcitabine and oxaliplatin led to a statistically significant and clinically meaningful improvement in survival vs rituximab (Rituxan) plus gemcitabine/oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplant.